Physician profile
Michael E Hymbaugh
NPI 1053529727
$16,008.06
in general payments reported to CMS, 2019-2025
16 companies · $5,283 in 2025
The $5,283 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $6,859 · 2021: $492 · 2022: $381 · 2023: $821 · 2024: $1,265 · 2025: $5,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,763 · Consulting Fee: $3,270 · Travel and Lodging: $316 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,763.18 |
| Consulting Fee | $3,270.00 |
| Travel and Lodging | $316.06 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,253.07 | 2019-2025 | Yeztugo, Biktarvy, Descovy |
| Viiv Healthcare Company | $1,988.82 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Janssen Products, Lp | $546.74 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $375.78 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Napo Pharmaceuticals INC | $284.94 | 2020-2024 | Mytesi |
| Janssen Biotech, INC. | $163.89 | 2019-2021 | |
| Theratechnologies INC. | $124.64 | 2019-2024 | Trogarzo, Egrifta |
| Abbott Laboratories | $110.38 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $45.24 | 2020-2025 | Zepbound |
| Insulet Corporation | $24.93 | 2024 | Omnipod |
| Janssen Scientific Affairs, LLC | $18.41 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $15.93 | 2020 | |
| Exact Sciences Corporation | $14.84 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $13.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.41 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $13.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hymbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.